What should I do if I develop resistance to Ado-trastuzumab emtansine?

One of the mechanisms of resistance to Ado-trastuzumab emtansine is hypoxia, a common hallmark of cancer. Because it regulates the transport of receptor proteins, it may have a negative impact on targeted therapies. In clinical studies, it was observed that hypoxia causes the transfer of caveolin-1 from cytoplasmic vesicles to the plasma membrane, subsequently leading to poor cellular uptake of the drug.

An alternative drug that may be used to combat resistance to trastuzumab is ARX788, a novel anti-HER2 antibody-drug conjugate. At present, cells that are resistant to trastuzumab overexpress Yes, which in turn activates EGFR and PI3K. In clinical studies, it is recommended to use Yes and HER2 inhibitors at the same time in an attempt to better combat the resistance to trastuzumab. Another drug found to be able to overcome drug resistance is SYD985, a second-generation antibody-drug conjugate. Dihydroartemisinin increases the effects of trastuzumab on microtubules and overall invasive resistance HER2 tumors. This is the resistance result of trastuzumab expressed in clinical studies. If the patient develops resistance, please inform your doctor in time and do not adjust the drug dosage yourself.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. Only eligible patients can be reimbursed. SpecificationsThe price of 100mg per box may be around 20,000 yuan. This drug is a strictly controlled drug. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.